药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Etidronic acid
Ponatinib
The risk or severity of adverse effects can be increased when Aldosterone is combined with Ponatinib.
Etidronic acid
Carfilzomib
The risk or severity of adverse effects can be increased when Aldosterone is combined with Carfilzomib.
Etidronic acid
Teriflunomide
The risk or severity of adverse effects can be increased when Aldosterone is combined with Teriflunomide.
Etidronic acid
Belimumab
The risk or severity of adverse effects can be increased when Aldosterone is combined with Belimumab.
Etidronic acid
Ruxolitinib
The risk or severity of adverse effects can be increased when Aldosterone is combined with Ruxolitinib.
Etidronic acid
Eribulin
The risk or severity of adverse effects can be increased when Aldosterone is combined with Eribulin.
Etidronic acid
Wortmannin
The risk or severity of adverse effects can be increased when Aldosterone is combined with Wortmannin.
Etidronic acid
Pralatrexate
The risk or severity of adverse effects can be increased when Aldosterone is combined with Pralatrexate.
Etidronic acid
Cabazitaxel
The risk or severity of adverse effects can be increased when Aldosterone is combined with Cabazitaxel.
Etidronic acid
Bendamustine
The risk or severity of adverse effects can be increased when Aldosterone is combined with Bendamustine.
Etidronic acid
Belatacept
The risk or severity of adverse effects can be increased when Aldosterone is combined with Belatacept.
Etidronic acid
Abetimus
The risk or severity of adverse effects can be increased when Aldosterone is combined with Abetimus.
Etidronic acid
Bosutinib
The risk or severity of adverse effects can be increased when Aldosterone is combined with Bosutinib.
Etidronic acid
Mepolizumab
The risk or severity of adverse effects can be increased when Aldosterone is combined with Mepolizumab.
Etidronic acid
Panobinostat
The risk or severity of adverse effects can be increased when Aldosterone is combined with Panobinostat.
Etidronic acid
Pazopanib
The risk or severity of adverse effects can be increased when Aldosterone is combined with Pazopanib.
Etidronic acid
Trastuzumab emtansine
The risk or severity of adverse effects can be increased when Aldosterone is combined with Trastuzumab emtansine.
Etidronic acid
Human interferon omega-1
The risk or severity of adverse effects can be increased when Aldosterone is combined with Human interferon omega-1.
Etidronic acid
Briakinumab
The risk or severity of adverse effects can be increased when Aldosterone is combined with Briakinumab.
Etidronic acid
Gallium nitrate
The risk or severity of adverse effects can be increased when Aldosterone is combined with Gallium nitrate.